TD Asset Management Inc Has $1.51 Million Stock Holdings in Janux Therapeutics, Inc. $JANX

TD Asset Management Inc lessened its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 0.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 65,236 shares of the company’s stock after selling 400 shares during the quarter. TD Asset Management Inc owned approximately 0.11% of Janux Therapeutics worth $1,507,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC grew its stake in shares of Janux Therapeutics by 54.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 9,033 shares of the company’s stock worth $244,000 after buying an additional 3,168 shares during the last quarter. New York State Common Retirement Fund grew its stake in shares of Janux Therapeutics by 3.0% during the first quarter. New York State Common Retirement Fund now owns 16,435 shares of the company’s stock worth $444,000 after buying an additional 471 shares during the last quarter. Cubist Systematic Strategies LLC grew its stake in shares of Janux Therapeutics by 88.0% during the first quarter. Cubist Systematic Strategies LLC now owns 75,860 shares of the company’s stock worth $2,048,000 after buying an additional 35,511 shares during the last quarter. KBC Group NV bought a new stake in shares of Janux Therapeutics during the first quarter worth $66,000. Finally, GAMMA Investing LLC grew its stake in shares of Janux Therapeutics by 1,574.0% in the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company’s stock worth $45,000 after purchasing an additional 1,574 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Trading Down 1.8%

Shares of NASDAQ JANX opened at $26.34 on Thursday. The firm’s 50-day moving average price is $24.32 and its 200-day moving average price is $25.29. Janux Therapeutics, Inc. has a 1-year low of $21.73 and a 1-year high of $71.71. The firm has a market capitalization of $1.58 billion, a P/E ratio of -14.63 and a beta of 2.82.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.07). Equities research analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on JANX. Raymond James Financial began coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They issued an “outperform” rating and a $65.00 price objective on the stock. Guggenheim began coverage on shares of Janux Therapeutics in a research note on Wednesday, September 3rd. They issued a “buy” rating and a $72.00 price objective on the stock. Stifel Nicolaus reissued a “buy” rating and issued a $45.00 price objective on shares of Janux Therapeutics in a research note on Wednesday, September 10th. Barclays started coverage on shares of Janux Therapeutics in a report on Wednesday, September 17th. They issued an “overweight” rating and a $47.00 target price on the stock. Finally, Piper Sandler started coverage on shares of Janux Therapeutics in a report on Monday, August 18th. They issued an “overweight” rating and a $42.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Janux Therapeutics has an average rating of “Moderate Buy” and an average price target of $78.31.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.